In Initial Assessments, NICE Recommends Celgene's Thalidomide And J&J's Bortezomib
Thalidomide and bortezomib could be recommended for in multiple myeloma, but NICE rejects Novartis' Xolair for children with severe allergic asthma.
Thalidomide and bortezomib could be recommended for in multiple myeloma, but NICE rejects Novartis' Xolair for children with severe allergic asthma.